Literature DB >> 28774210

Evaluation of microwave ablation of liver malignancy with enabled constant spatial energy control to achieve a predictable spherical ablation zone.

Thomas J Vogl1, Lajos M Basten1, Nour-Eldin A Nour-Eldin1,2, Benjamin Kaltenbach1, Boris Bodelle1, Julian L Wichmann1, Hanns Ackermann3, Nagy N N Naguib1,4.   

Abstract

OBJECTIVES: To evaluate the clinical performance of a new microwave ablation (MWA) system with enabled constant spatial energy control (ECSEC) to achieve spherical ablation zones in the treatment of liver malignancies.
MATERIALS AND METHODS: In this retrospective study, 56 hepatic tumours in 48 patients (23 men, 25 women; mean age: 59.6 years) were treated using a new high-frequency MWA-system with ECSEC. Parameters evaluated were technical success, technical efficacy, tumour diameter, tumour and ablation volume, complication rate, 90-day mortality, local tumour progression (LTP) at the 12-month follow-up, ablative margin and ablation zone sphericity. These parameters were compared using the Kruskal-Wallis test with the same parameters collected retrospectively from cohorts of patients treated with conventional high-frequency (HF) MWA (n = 20) or low-frequency (LF) MWA (n = 20).
RESULTS: Technical success was achieved in all interventions. The technical efficacy was 100% (ECSEC) vs. 100% (LF-MWA) vs. 95% (HF-MWA). There were no intra-procedural deaths or major complications. Minor complications occurred in 3.57% (2/56), 0% (0/20) and 0% (0/20) of the patients, respectively. The one-year mortality rate was 16.1% (9/56), 15% (3/20) and 10% (2/20), respectively. The LTP was 3.57% (2/56), 5% (1/20) and 5% (1/20), respectively. The median deviation from ideal sphericity (1.0) was 0.135 (ECSEC) vs. 0.344 (LF-MWA) vs. 0.314 (HF-MWA) (p < 0.001). The absolute minimal ablative margin was 8.1 vs. 2.3 vs. 3.1 mm (p < 0.001).
CONCLUSIONS: Microwave ablation of liver malignancies is a safe and efficient treatment independent of the system used. Hepatic MWA with ECSEC achieves significantly more spherical ablation zones and higher minimal ablative margins.

Entities:  

Keywords:  Clinical trials-thermal ablation; radiofrequency/microwave; thermal ablation

Mesh:

Year:  2017        PMID: 28774210     DOI: 10.1080/02656736.2017.1358408

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  12 in total

1.  Volumetric 3D assessment of ablation zones after thermal ablation of colorectal liver metastases to improve prediction of local tumor progression.

Authors:  Elena A Kaye; Francois H Cornelis; Elena N Petre; Neelam Tyagi; Waleed Shady; Weiji Shi; Zhigang Zhang; Stephen B Solomon; Constantinos T Sofocleous; Jeremy C Durack
Journal:  Eur Radiol       Date:  2018-11-06       Impact factor: 5.315

2.  Large nearly spherical ablation zones are achieved with simultaneous multi-antenna microwave ablation applied to treat liver tumours.

Authors:  Roberto Luigi Cazzato; Pierre De Marini; Loïc Leclerc; Danoob Dalili; Guillaume Koch; Pramod Rao; Pierre Auloge; Julien Garnon; Afshin Gangi
Journal:  Eur Radiol       Date:  2019-09-16       Impact factor: 5.315

Review 3.  Thermal Ablation of Metastatic Colon Cancer to the Liver.

Authors:  Juan C Camacho; Elena N Petre; Constantinos T Sofocleous
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

4.  Performance of the Emprint and Amica Microwave Ablation Systems in ex vivo Porcine Livers: Sphericity and Reproducibility Versus Size.

Authors:  P Hendriks; W E M Berkhout; C I Kaanen; J H Sluijter; I J Visser; J J van den Dobbelsteen; L F de Geus-Oei; A G Webb; M C Burgmans
Journal:  Cardiovasc Intervent Radiol       Date:  2021-01-18       Impact factor: 2.740

Review 5.  Liver microwave ablation: a systematic review of various FDA-approved systems.

Authors:  Simeon J S Ruiter; Wouter J Heerink; Koert P de Jong
Journal:  Eur Radiol       Date:  2018-11-30       Impact factor: 5.315

6.  Direction of Tissue Contraction after Microwave Ablation: A Comparative Experimental Study in Ex Vivo Bovine Liver.

Authors:  Junhyok Lee; Hyunchul Rhim; Min Woo Lee; Tae Wook Kang; Kyoung Doo Song; Jeong Kyong Lee
Journal:  Korean J Radiol       Date:  2022-01       Impact factor: 3.500

7.  Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial.

Authors:  Aleksandar Radosevic; Rita Quesada; Clara Serlavos; Juan Sánchez; Ander Zugazaga; Ana Sierra; Susana Coll; Marcos Busto; Guadalupe Aguilar; Daniel Flores; Javier Arce; José María Maiques; Montserrat Garcia-Retortillo; José Antonio Carrion; Laura Visa; María Villamonte; Eva Pueyo; Enrique Berjano; Macarena Trujillo; Patricia Sánchez-Velázquez; Luís Grande; Fernando Burdio
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.379

8.  A prospective randomized trial comparing microwave and radiofrequency ablation for the treatment of liver metastases using a dual ablation system ─ The Mira study.

Authors:  Thomas J Vogl; Yousef Jaraysa; Simon S Martin; Tatjana Gruber-Rouh; Rock H Savage; Nour-Eldin A Nour-Eldin; Amela Mehmedovic
Journal:  Eur J Radiol Open       Date:  2022-01-28

9.  Multi-institutional analysis of outcomes for thermosphere microwave ablation treatment of colorectal liver metastases: the SMAC study.

Authors:  Francesco De Cobelli; Marco Calandri; Angelo Della Corte; Roberta Sirovich; Carlo Gazzera; Paolo Della Vigna; Guido Bonomo; Gianluca Maria Varano; Daniele Maiettini; Giovanni Mauri; Nicola Camisassi; Stephanie Steidler; Francesca Ratti; Simone Gusmini; Monica Ronzoni; Luca Aldrighetti; Bruno C Odisio; Patrizia Racca; Paolo Fonio; Andrea Veltri; Franco Orsi
Journal:  Eur Radiol       Date:  2022-01-29       Impact factor: 7.034

10.  Artefact and ablation performance of an MR-conditional high-power microwave system in bovine livers: an ex vivo study.

Authors:  Antonia Grimm; Moritz Winkelmann; Jakob Weiß; Georg Gohla; Gunnar Blumenstock; Konstantin Nikolaou; Stephan Clasen; Rüdiger Hoffmann
Journal:  Eur Radiol Exp       Date:  2019-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.